Digest Network Come funziona
Network
/
Società
Ge
Non verificato

Genentech

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

92 comunicati stampa

Guarda tutti i comunicati
15/07/2026
Industria
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Sanità
Farmaceutica
Salute
Oncologia
FDA Grants Priority Review to Genentech’s Gazyva for Adults With Primary Membranous Nephropathy
Fonte
Genentech
Emittente
Business Wire
1.00
0
07/07/2026
Biotecnologia
Farmaceutica
Salute
Industria
Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC
Fonte
Genentech
Emittente
Business Wire
1.00
0
02/07/2026
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Industria
Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer
Fonte
Genentech
Emittente
Business Wire
1.00
0
30/06/2026
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Ottica
FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
Fonte
Genentech
Emittente
Business Wire
1.00
0
18/06/2026
Industria
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma
Fonte
Genentech
Emittente
Business Wire
1.00
0
11/06/2026
Industria
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer
Fonte
Genentech
Emittente
Business Wire
1.00
0
02/06/2026
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting
Fonte
Genentech
Emittente
Business Wire
1.00
0
01/06/2026
Eventi
Web e Social Network
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Fonte
Genentech
Emittente
Business Wire
1.00
0
19/05/2026
Eventi
Fiere
Industria
Biotecnologia
Farmaceutica
Salute
Oncologia
Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer
Fonte
Genentech
Emittente
Business Wire
1.00
0
15/05/2026
Industria
Biologia
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Oncologia
Scienza
Medicina - Varie
FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
Fonte
Genentech
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0